Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
11 pending office actions • 7 art units • 11 examiners • 0 of 11 (0%) have an AI response strategy ready • 16 patents granted in the last 365 days
Eisai R&D Management Co., Ltd. is currently prosecuting 11 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 11 matters are spread across 7 distinct art units, reflecting the complex nature of pharmaceutical patenting. There are 11 distinct examiners assigned to these cases, resulting in a ratio of 1 examiner to each pending action. This distribution across 7 art units suggests that the 11 pending actions cover a variety of biotechnological sub-fields. Each action will be decided by a different individual at the patent office.
The busiest examiner, LEWIS, CAMRYN BROOKE, is responsible for 1 pending office action. Because each of the 11 examiners holds only 1 action, the company faces 11 unique sets of examiner expectations. There is no concentration of cases, as the 11 distinct examiners each manage a single pending matter. Practitioners should develop 11 individualized strategies to address the 11 pending office actions. The 7 distinct art units provide the technical framework for these 11 separate prosecution paths.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (9%) |
| §103 only | 4 (36%) |
| §112 only | 1 (9%) |
| Double-patenting + other | 3 (27%) |
| Multi-statute (no §101) | 2 (18%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEWIS, CAMRYN BROOKE | 1 | 5.0% | +11.1% |
| JARRELL, NOBLE E | 1 | 81.1% | +9.7% |
| CHEN, PO-CHIH | 1 | 74.2% | +14.8% |
| JAVANMARD, SAHAR | 1 | 64.8% | +34.1% |
| LEE, YIE CHIA | 1 | 69.2% | +46.6% |
| ROONEY, NORA MAUREEN | 1 | 60.3% | +23.6% |
| SIMMONS, CHRIS E | 1 | 34.1% | +19.4% |
| ISMAIL, REHANA | 1 | 75.8% | +34.8% |
| BERHANE, SELAM | 1 | 58.4% | +56.7% |
| BUTTICE, AUDREY L | 1 | 47.9% | +25.9% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18863738 | SOLID FORM OF PPAR-GAMMA MODULATORS AND METHODS OF USE | JARRELL, NOBLE E | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18028039 | PHARMACEUTICAL COMPOSITION | ROONEY, NORA MAUREEN | 133d overdue |
| 17757825 | METHOD FOR PRODUCING ERIBULIN-BASED ANTIBODY-DRUG CONJUGATE | BUTTICE, AUDREY L | 37d overdue |
| 19161653 | INFORMATION PROCESSING DEVICE, INFORMATION PROCESSING METHOD, PROGRAM, AND STORAGE MEDIUM | LEWIS, CAMRYN BROOKE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18028039 | PHARMACEUTICAL COMPOSITION | ROONEY, NORA MAUREEN | 133d overdue |
| 17757825 | METHOD FOR PRODUCING ERIBULIN-BASED ANTIBODY-DRUG CONJUGATE | BUTTICE, AUDREY L | 37d overdue |
| 18188716 | EZH2 INHIBITORS FOR TREATING LYMPHOMA | SIMMONS, CHRIS E | 42d |
| 19161653 | INFORMATION PROCESSING DEVICE, INFORMATION PROCESSING METHOD, PROGRAM, AND STORAGE MEDIUM | LEWIS, CAMRYN BROOKE | — |
| 18846909 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF PARKINSON'S DISEASE | CHEN, PO-CHIH | — |
| 18722917 | CRYSTAL OF SUBSTITUTED PIPERIDINE COMPOUND, SALTS OF SUBSTITUTED PIPERIDINE COMPOUND, AND CRYSTALS THEREOF | JAVANMARD, SAHAR | — |
| 18577174 | BIOMARKERS FOR ALZHEIMER'S DISEASE TREATMENT | LEE, YIE CHIA | — |
| 18009115 | METHODS FOR TREATING CANCER OR VON-HIPPEL LINDAU DISEASE USING A COMBINATION OF A HIF-2 ALPHA INHIBITOR AND LENVATINIB | ISMAIL, REHANA | — |
| Art Unit | Apps |
|---|---|
| 3683 | 1 |
| 1641 | 1 |
| 1622 | 1 |
| 1625 | 1 |
| 1675 | 1 |
| 1647 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19161653 | INFORMATION PROCESSING DEVICE, INFORMATION PROCESSING METHOD, PROGRAM, AND STORAGE MEDIUM | LEWIS, CAMRYN BROOKE | 3683 | §101§103§112 | Non-Final OA | — | Pending | Sep 02, 2025 |
| 18863738 | SOLID FORM OF PPAR-GAMMA MODULATORS AND METHODS OF USE | JARRELL, NOBLE E | — | §112 | Non-Final OA | — | Pending | Nov 07, 2024 |
| 18846909 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF PARKINSON'S DISEASE | CHEN, PO-CHIH | — | §103 | Non-Final OA | — | Pending | Sep 13, 2024 |
| 18722917 | CRYSTAL OF SUBSTITUTED PIPERIDINE COMPOUND, SALTS OF SUBSTITUTED PIPERIDINE COMPOUND, AND CRYSTALS THEREOF | JAVANMARD, SAHAR | — | §103Other | Non-Final OA | — | Pending | Jun 21, 2024 |
| 18577174 | BIOMARKERS FOR ALZHEIMER'S DISEASE TREATMENT | LEE, YIE CHIA | — | §103§112DP | Non-Final OA | — | Pending | Jan 05, 2024 |
| 18028039 | PHARMACEUTICAL COMPOSITION | ROONEY, NORA MAUREEN | 1641 | §103§112 | Final Rejection | 133d overdue | Pending | Mar 23, 2023 |
| 18188716 | EZH2 INHIBITORS FOR TREATING LYMPHOMA | SIMMONS, CHRIS E | 1622 | §103Other | Non-Final OA | 42d | Pending | Mar 23, 2023 |
| 18009115 | METHODS FOR TREATING CANCER OR VON-HIPPEL LINDAU DISEASE USING A COMBINATION OF A HIF-2 ALPHA INHIBITOR AND LENVATINIB | ISMAIL, REHANA | 1625 | §103DP | Final Rejection | — | Pending | Dec 08, 2022 |
| 17906660 | HIGH CONCENTRATION ANTI-Abeta PROTOFIBRIL ANTIBODY FORMULATIONS AND METHODS OF USE THEREOF | BERHANE, SELAM | 1675 | §103 | Final Rejection | — | Pending | Sep 19, 2022 |
| 17757825 | METHOD FOR PRODUCING ERIBULIN-BASED ANTIBODY-DRUG CONJUGATE | BUTTICE, AUDREY L | 1647 | §102§103Other | Final Rejection | 37d overdue | Pending | Jun 21, 2022 |
| 17757672 | USE OF LEMBOREXANT FOR TREATING INSOMNIA | MOU, LIYUAN | 1628 | §103DP | Non-Final OA | — | Pending | Jun 17, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial